SuviCa, Inc. Awarded SBIR Phase 1 NCI Contract To Study Its Lead Molecules In Preclinical Models Of Head And Neck Cancer

September 24th, 2013:  SuviCa, Inc., a private cancer drug discovery and development company that applies its proprietary screen to identify small molecule anticancer agents, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 contract from the National Cancer Institute (NCI).  Through the terms of the contract, SuviCa will discover and develop small molecule drugs against Head and Neck Cancers (HNC).  The focus is on drug candidates that target processes critical for re-growth of the cancer after radiation treatment.  SuviCa will perform preliminary pharmacokinetics and toxicity studies and test the efficacy of a proprietary drug candidate in combination with radiation in preclinical models of human HNC.  Full Release attached here:  SuviCa Press Release – NCI Contract Award – 130924.